Novavax, Inc. [NVAX] stock prices are up 0.72% to $5.61 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NVAX shares have gain 27.21% over the last week, with a monthly amount glided 49.20%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 29, February 2024, Novavax to Participate in TD Cowen’s 44th Annual Health Care Conference. In a post published today on Yahoo Finance, Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen’s 44th Annual Health Care Conference.
From an analyst’s perspective:
Novavax, Inc. [NASDAQ: NVAX] stock has seen the most recent analyst activity on August 09, 2023, when B. Riley Securities upgraded its rating to a Buy but kept the price target unchanged to $15 for it. Previously, TD Cowen downgraded its rating to Market Perform on April 20, 2023, and dropped its price target to $10. On March 01, 2023, downgrade downgraded it’s rating to Neutral and revised its price target to $10 on the stock. B. Riley Securities reiterated its Buy rating and decreased its price target to $37 on January 09, 2023. H.C. Wainwright reiterated its recommendation of a Buy and reduced its price target to $110 on December 30, 2022. In a note dated September 22, 2022, JP Morgan downgraded an Underweight rating on this stock and revised its target price from $132 to $27.
The stock price of Novavax, Inc. [NVAX] has been fluctuating between $3.53 and $11.36 over the past year. Currently, Wall Street analysts expect the stock to reach $174 within the next 12 months. Novavax, Inc. [NASDAQ: NVAX] shares were valued at $5.61 at the most recent close of the market. An investor can expect a potential return of 3001.6% based on the average NVAX price forecast.
Analyzing the NVAX fundamentals
The Novavax, Inc. [NASDAQ:NVAX] reported sales of 983.71M for trailing twelve months, representing a drop of -18.48%. Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at -0.77%, Pretax Profit Margin comes in at -0.68%, and Net Profit Margin reading is -0.67%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is 0.74 and Total Capital is -3.32. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.33.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.41 points at the first support level, and at 5.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.81, and for the 2nd resistance point, it is at 6.01.
Novavax, Inc. [NVAX] reported earnings per share of -$1.44 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.45/share, meaning a difference of -$0.99 and a surprise factor of -220.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.26 per share as compared to estimates of -$1.83 per share, a difference of $0.57 representing a surprise of 31.10%.
Ratios To Look Out For
It’s worth pointing out that Novavax, Inc. [NASDAQ:NVAX]’s Current Ratio is 0.70. Further, the Quick Ratio stands at 0.67, while the Cash Ratio is 0.44. Considering the valuation of this stock, the price to sales ratio is 0.80.
Transactions by insiders
Recent insider trading involved Glenn Gregory M, President, R&D, that happened on Mar 10 ’23 when 1000.0 shares were purchased. President, R&D, Glenn Gregory M completed a deal on Mar 07 ’23 to buy 2000.0 shares.
